Rechercher des projets européens

34 projets européens trouvés

Recherche sur 125080 projets européens

 TERMINÉ 
"Obesity and associated metabolic diseases such as type 2 diabetes are increasing worldwide and are the result of complex gene-environment interactions. Recent studies indicate that socio-demographic and environmental factors are more important for disease development than genetics, and we and others have demonstrated that the gut microbiota can be considered an environmental factor that contribut ...
Voir le projet

 1

 TERMINÉ 

The Neurobiology of Decision-Making in Eating - Innovative Tools (NUDGE-IT)

Date du début: 1 janv. 2014, Date de fin: 31 déc. 2018,

Nudge-it engages internationally leading experts in the neurobiology of motivational behaviour, the neuroscience of reward pathways, the neuroendocrinology of homeostatic regulation of appetite, experimental psychology, functional brain imaging, behavioural economics, and computational modelling. They will work together to develop new tools and approaches that can provide the evidence needed to in ...
Voir le projet

 10

 TERMINÉ 

Vaccination In Atherosclerosis (VIA)

Date du début: 1 déc. 2013, Date de fin: 30 nov. 2018,

"Cardiovascular disease (CVD) is still a leading cause of death in the European Union (EU) accounting for nearly half of all deaths in Europe (48%). In addition, CVD complications lead to a vast number of hospitalizations and thus to a great burden of health care costs in the EU. Atherosclerosis and its final complication, plaque rupture and subsequent infarct in heart or brain, is the main underl ...
Voir le projet

 12

 TERMINÉ 

Metagenomics in Cardiometabolic Diseases (METACARDIS)

Date du début: 1 nov. 2012, Date de fin: 31 oct. 2018,

... siological role of these markers will be tested in both preclinical models and replication cohorts allowing the study of CMD progression in patients collected in three European clinical centres of excellence. Their impact on host gene transcription will be characterised in patients selected for typical features of CMD evolution. Application of computational models and visualisation tools to comple ...
Voir le projet

 18

 TERMINÉ 

The importance of the epigenome in tumour development and recurrence (EpiBrain)

Date du début: 1 mai 2014, Date de fin: 30 avr. 2018,

I aim to develop methods to reverse epigenetic anomalies in cancer stem cells (CSCs) to switch off the unlimited cell division and cancer growth and to understand the involvement of epigenetics in tumour development and recurrence. Epigenetic alterations are observed at the earliest stages of neoplasia within stem cells. Importantly, the alterations are reversible and can potentially be “treated”. ...
Voir le projet

 1

 TERMINÉ 

SYSTEMS GLYCOBIOLOGY OF GASTRIC CANCER (GASTRICGLYCOEXPLORER)

Date du début: 1 mai 2013, Date de fin: 30 avr. 2018,

This ITN is built around the biological question of O-glycosylation in gastric cancer for training in systems glycobiology. For meeting the needs of the research goal and for training for future systems glycobiology operations, cross disciplinary international institutes have been identified with top level state-of-the-art glycobioanalytical, glycotechnological and glycobioinformatics platforms. T ...
Voir le projet

 13

 TERMINÉ 
"Through combining basic pre-clinical and clinical research, network analysis and computational modelling, RESOLVE aims at resolving the disturbed dynamics and mechanisms underlying the high triglyceride (HTG) and low high-density lipoprotein cholesterol (HDL-C) phenotype and insulin resistance in patients with metabolic syndrome (MetS) and its associated co-morbidities (cardiovascular disease, CV ...
Voir le projet

 14

 TERMINÉ 

European Medical Information Framework (EMIF)

Date du début: 1 janv. 2013, Date de fin: 31 déc. 2017,

In response to the need to tackle increasingly complex medical research questions, a growing amount of human health data is being collected, either in routine Electronic Healthcare Record (EHR) databases, through research-driven cohort studies, in biobanks or related efforts. However, data sources are typically fragmented and contain information gaps which prevent their full exploitation. EMIF aim ...
Voir le projet

 64

 TERMINÉ 

Universal Flu Vaccine (UNIVACFLU)

Date du début: 1 nov. 2013, Date de fin: 31 oct. 2017,

... aralleled in any single EU country. The training program is extensive and builds on the integrated added values of complementing expertise and the full access to state-of-the- art technologies and excellent training environments. This unique consortium has 2 SMEs as fully committed members to guarantee strong intersectoral cooperation between industry and academia.The partners represent 6 leading ...
Voir le projet

 8

 TERMINÉ 
"The overall objective is to develop a novel preventative intervention for the blinding disease retinopathy of prematurity (ROP) and other complications of prematurity. The PREVENTROP consortium proposes to conduct preclinical studies (pharmacological, pharmacodynamics, pharmacokinetics and toxicological) in models and/or clinical studies (including phase III clinical trial) of an EU designated o ...
Voir le projet

 10

 TERMINÉ 

Advanced Immunization Technologies (ADITEC)

Date du début: 1 oct. 2011, Date de fin: 30 sept. 2017,

Vaccines so far have been developed mostly by following an empiric approach. To prevent and possibly cure unresolved and emerging infectious diseases we need to fully exploit the potential of the human immune system. Progress in science and technology makes it possible to achieve what was previously deemed impossible. The scope of this project is to produce knowledge necessary to develop novel and ...
Voir le projet

 53

 TERMINÉ 

The European non-coding RNA network (RNATRAIN)

Date du début: 1 oct. 2013, Date de fin: 30 sept. 2017,

"Non-coding RNA (ncRNA) is a new research field in rapid development. It holds the potential to explain many fundamental biological phenomena and there is a vast prospective for the development of ncRNA-derived diagnostic and therapeutic tools. Hence, biotech and pharmaceutical companies are actively looking into this unexplored territory for novel targets. Therefore, there is a substantial and un ...
Voir le projet

 11

 TERMINÉ 

Universal Influenza Vaccines Secured (UNISEC)

Date du début: 1 oct. 2013, Date de fin: 30 sept. 2017,

UNISEC brings together a European consortium of 3 University partners, 5 National Health Institutes and 3 SMEs, all with leading expertise in influenza vaccine research and development, to work on promising recently developed concepts for a universal influenza vaccine. The consortium is exceptionally strong, interdisciplinary and intersectional in nature, and encompasses a unique combination of sc ...
Voir le projet

 15

 TERMINÉ 
Euroclast proposes a research training program on osteoclast biology in the context of osteoclast-driven diseases. Osteoclasts are the complex, multinuclear cells responsible for bone breakdown. Many diseases of osteoclast malfunctioning manifest in bone loss, for example, osteoporosis, cancer-induced bone disease, periodontitis, or rheumatoid arthritis, all conditions set to increase in an ageing ...
Voir le projet

 11

 TERMINÉ 
TRANSLINK is a project devoted to assessing the mid-to long-term risk factors and improve the outcome of animal (bovine/porcine)-derived Bioprosthetic Heart Valve (BHV) implants. 300,000 patients/year benefit from BHV, a major healthcare problem (second most frequent cardiac surgery). BHV clinical outcome suffers from late dysfunctions restricting their application to older recipients. Based on a ...
Voir le projet

 14

 TERMINÉ 
... to exploit the complimentary expertise of EU and third country research or-ganisations through knowledge sharing and transfer between countries. This will be achieved by establishing a Network of Excellence (NoE) that will incorporate staff secondments for the purpose of networking, training activities, workshops, and joint research. Thus, this proposal will foster a mutual understanding of the d ...
Voir le projet

 3

 TERMINÉ 
"This proposal concerns an outgoing fellowship for Samuel Lundin (SL), PhD, Dept. of Microbiology and Immunology, University of Gothenburg. To further develop and substantially boost his scientific career, SL will for two years visit the laboratory of Professor Barry Marshall, University of Western Australia, Perth, Australia.SL has a good track record in science, but lacks crucial skills in bioin ...
Voir le projet

 1

 TERMINÉ 
Though of tremendous benefit, the overuse of antibiotics has lead to the emergence of antibiotic resistance and may cause adverse events that impact on patient healthcare. Current diagnostic tools for facilitating the appropriate use of antibiotics in patients are inadequate.We will establish a broad-based strategy (not limited to a particular antibiotic group) that can be implemented on a broad s ...
Voir le projet

 7

 TERMINÉ 

Virtual Prototyping of Tactile Displays (PROTOTOUCH)

Date du début: 1 mai 2013, Date de fin: 30 avr. 2017,

"It is estimated that touch screen module revenues will reach $23.9 billion by 2017. These user interfaces have become one of the most common input devices for digital media, e.g. in mobile phones and computers. Current devices incorporate relatively primitive vibrotactile haptic-feedback. The aim of PROTOTOUCH is to develop tactile displays with high fidelity haptic recognition, so that buttons w ...
Voir le projet

 10

 TERMINÉ 
Obesity is a world-wide epidemic and currently about 350 million people suffer from diabetes, resulting in more than 3 million deaths per year. While the gut microbiota has been identified as a contributing factor to obesity and insulin resistance in mice and humans, the underlying disease-causing mechanisms are yet to be defined. The aim of this proposal is to investigate the interactions between ...
Voir le projet

 1

 TERMINÉ 

Co-morbidity in relation to Aids (COBRA)

Date du début: 1 mars 2013, Date de fin: 28 févr. 2017,

Persons with HIV on combination antiretroviral therapy (cART) are at increased risk of the premature development of age-associated non-communicable comorbidities (AANCC), including cardiovascular, chronic kidney, liver and pulmonary disease, diabetes mellitus, osteoporosis, non-AIDS associated malignancies, and neurocognitive impairment. It has therefore been hypothesised that such individuals, de ...
Voir le projet

 12

 TERMINÉ 
Optimal, healthy pregnancy followed by normal birth is the ideal. Caesarean section (CS) doubles the risk of mortality and morbidity (hysterectomy, blood transfusion), and increases the risk of postnatal infection by 5, compared with vaginal birth (WHO Global Survey on Maternal and Perinatal Health). The European Perinatal Health Report (2008) notes “widespread concern” over rising CS rates, which ...
Voir le projet

 11

 TERMINÉ 

Biomarkers For Enhanced Vaccine Safety (BIOVACSAFE)

Date du début: 1 mars 2012, Date de fin: 31 déc. 2016,

BioVacSafe is a concise consortium of selected academic, public, and SME participants used to co-working in industry-led projects, organised into focused Activity Cores to generate knowledge and tools to benchmark licensed vaccine reactogenicity, and create practical and generalizable guidelines and techniques to enhance immunosafety of novel vaccines from pre-development to post-marketing surveil ...
Voir le projet

 24

 TERMINÉ 
Alzheimer’s disease (AD) is an ever-increasing public health concern among the aging population and is the most common form of dementia affecting more than 15 million individuals worldwide and around 5 million Europeans. The direct and indirect costs of AD and other dementias amount to more than €440,000 million each year (www.alz.org, 2010).Even modest therapeutic advances that delay disease onse ...
Voir le projet

 17

 TERMINÉ 
The capacity of zoonotic RNA viruses to emerge as major agents of human disease can appear limitless. Current intervention strategies have demonstrated limited success. Rapid, innovative and effective solutions are needed to reduce the apparently accelerating process of zoonotic disease emergence. We will study the following zoonotic viruses with epidemic potential in Europe: influenza virus, hepa ...
Voir le projet

 20

 TERMINÉ 

A Gateway to European Kidney Research Resources - KidneyConnect (KidneyConnect)

Date du début: 1 août 2013, Date de fin: 31 juil. 2016,

... costs. Leading European research has indisputably pointed that the kidney filtration barrier and its epithelial cell, the podocyte, is a common denominator for the DCC-diseases. However, European excellence and expertise have remained uncoordinated in separate pockets and, consequently, underutilised for full societal benefits and capacity creation to combat the challenges of diabetic, hypertensi ...
Voir le projet

 19

 TERMINÉ 
HILYSENS II is based on the 2-year HILYSENS research and development project (started November 2010) funded by the ‘Research for the Benefit of SMEs’ program of the European Commission's Seventh Framework Programme (FP7). HILYSENS II proposes Demonstration Activities for the prototype HILYSENS Lab-on-a-Chip developed during the successful research and development project, which was designed as a s ...
Voir le projet

 5

 TERMINÉ 
"The DIABAT project will employ knowledge of the function, dysfunction and physiological regulation of brown adipocytes to develop innovative therapeutic and preventive strategies for type 2 diabetes. Brown adipose tissue (BAT) is currently a worldwide recognized target to combat obesity and diabetes due to last years re-discovery of functional BAT in adult humans by several of the members of the ...
Voir le projet

 22

 TERMINÉ 
Mitochondrial DNA (mtDNA) deletions accumulate in aged post-mitotic tissue and in individuals with neurodegenerative diseases, leading to local energy defects. Understanding the mechanism of mtDNA deletion formation is an essential step in trying to prevent their occurrence.My hypothesis is that mtDNA deletions occur during mtDNA repair via a double strand break (DSB) repair pathway. I will addres ...
Voir le projet

 2

 TERMINÉ 

Towards a Sustainable and Affordable Healthcare (WE-CARE)

Date du début: 1 sept. 2013, Date de fin: 31 août 2015,

The aim of this action is to prepare the future for health research and innovation to contribute significantly towards a sustainable and affordable healthcare.EU-wide there is a clear and present need to contain healthcare costs to keep the healthcare affordable to all EU citizens. In many EU member states healthcare budgets are overstretched and in some states the growth of these budgets seem eve ...
Voir le projet

 7

 TERMINÉ 
Health-2-Market is an ambitious project aiming to boost the economic exploitation of EU-funded research results in the area of Health/life science. The project focuses on the actual Health/life science knowledge generators, namely the researchers, involved in EU-funded research in Health with a view to cultivate to them an enhanced innovation and entrepreneurial culture. More specifically, Health ...
Voir le projet

 10

 TERMINÉ 
... arch, the project enables holistic modeling of genetic correlates of human behavior and psychiatric conditions revealing new therapeutic avenues. The project embodies the work program by providing excellent international, multi-disciplinary, cross-modal academic training, establishing a solid yet dynamic basis for a prolific long-term scientific career for the Fellow. The project will increase the ...
Voir le projet

 2

 TERMINÉ 

Development of an oral Helicobacter Pylori vaccine (HELICOVAXOR)

Date du début: 1 oct. 2012, Date de fin: 31 déc. 2014,

"Helicobacter pylori infection is highly prevalent worldwide and is an important cause of gastritis, peptic ulcer disease, and significantly gastric cancer. Because eradication requires treatment with multidrug regimens, there exists a very strong need for a vaccine to prevent initial infection.Immunization with H pylori protein subunits in humans has shown adjuvant-related adverse effects and onl ...
Voir le projet

 11

 TERMINÉ 
This fellowship application proposes training in research that investigates the use of alpha-particle emitting radionuclides for targeted therapies of spread cancers. Eradicating disseminated disease using targeted alpha emitters is recognized as being very promising, but only a few research centres world-wide have the necessary infrastructure for advancing the field. Capacity must be held in trai ...
Voir le projet

 1